Header Image
News Room / Decision Diagnostics Receives Signed Term Sheet Agreement For $12.5 Million Revolving Credit Facility Which Will Complete DECN’s GenStrip Roll-Out Plan

Decision Diagnostics Receives Signed Term Sheet Agreement For $12.5 Million Revolving Credit Facility Which Will Complete DECN’s GenStrip Roll-Out Plan

-    New 5-year credit facility amounts to total annual financing of $250+ million
-    DECN reviewed competing offers, is now considering acquisitions pool proposals
-    Current trade debt of approx. $2.8 million to be retired, enhancing balance sheet
-    $12.5 million commercial line will NOT have an equity component

 

LOS ANGELES, CA - (ACCESSWIRE - October 29, 2013) - Decision Diagnostics Corp. (OTCBB:DECN) the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip™, the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that that the Company has received a Term Sheet Agreement for a $12.5 million revolving credit line from Alpha Credit Resources, LLC, a division of Platinum Credit Management LP of New York, NY. The new $12.5 million credit line will be totally equity free (no share dilution) and when matched with the company's current 1.8X sales turns per month (velocity), this credit facility will finance company sales of its GenStrip product line through $250+ million annually. The closing of the credit line and initial take-down is subject to DECN Board approval and the usual and customary documentation required for commercial credit and is expected early in November.

"Our credit line provides substantial resources for the Company to initiate our important, aggressive and revolutionary GenStrip business strategies," commented Keith Berman, DECN's Principal Officer, CFO and the GenStrip Program Director. "We want to make it clear to our shareholders, and the investing public, that our commercial lender Platinum Credit Management does not view Decision Diagnostics as a small business and is backing up their beliefs with $12.5 million. Thus, DECN never had to turn to stock market arbitrages such as equity lines of credit, equity participation agreements or any other type of toxic financing."

DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies. DECN's FDA cleared Shasta GenStrip™ product was first introduced to the market in late 2012 as a lower cost (50%) alternative for user/owners of Johnson and Johnson LifeScan OneTouch® Ultra®, Ultra2® and Ultra Mini® glucose meters.

Mr. Berman continued, "With the significant revenue streams GenStrip will produce, when coupled with our renewed access to $12.5 million of growth capital, we are now well positioned to complete the launch of GenStrip and embark on our mission. With a large and timely credit line coming into place, the company is now considering an offer for a $2.5 million M&A pool."

The company also reminds shareholders and all interested parties that it continues to air its new commercial video titled "GenStrip: A Patchwork of Life." The company plans on releasing a media schedule in the coming days. In the meantime, the extremely popular video is available for viewing at: http://shastagenstrip.com/shasta_ad.html or http://youtu.be/zzBuHxb-rlM.

Forward Looking Statements:

This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

For further information about Shasta GenStrip, please visit the company's Web Sites: http://www.decisiondiagnostics.com/ or http://www.shastagenstrip.com/.

GenStrip™ test strips are a product of Shasta Technologies, LLC and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan®, Inc. a Johnson & Johnson® Company, manufacturers and distributors of the OneTouch® Ultra® Family of Meters and OneTouch® Ultra® test strips.

Contact:
Decision Diagnostics Corp.
Keith Berman
(805) 446-2973
[email protected]

Top